Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent
anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) …

Abstract Approximately 40–50% of glioblastomas (GBM) overexpress epidermal growth
factor receptor (EGFR). Erlotinib is a specific and potent EGFR tyrosine kinase inhibitor …

Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …

Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …

Background Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic
target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma …

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active in
glioblastoma. We evaluated erlotinib efficacy in patients with first-relapse glioblastoma and …

Purpose: To evaluate the toxicity and maximum tolerated dose (MTD) of erlotinib plus
radiation therapy (RT) in patients with glioblastoma multiforme (GBM) in a multicenter phase …

Purpose This open-label, prospective, single-arm, phase II study combined erlotinib with
radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and …

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase
inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the …